New colistin population pharmacokinetic data in critically ILL patients suggesting an alternative loading dose rationale

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7324-7330

  Gregoire N ^a,b   Mimoz, O ^a,b,c   Megarbane B ^d   Comets, E ^e,f   Chatelier, D ^c   Lasocki, S ^g   Gauzit, R ^h   Balayn, D ^c   Gobin, P ^a,c   March, S ^a,b,c   Coueta, W ^e,f  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

^f UNIVERSITÉ PARIS DIDEROT   (France)

^g BICHAT HOSPITAL   (France)

^h HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID;

ADULT; AGED; ARTICLE; BACTERIAL CLEARANCE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; ELIMINATION HALF-LIFE; FEMALE; GRAM NEGATIVE INFECTION; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NEPHROTOXICITY; OPEN STUDY; STEADY STATE; TANDEM MASS SPECTROMETRY; VOLUME OF DISTRIBUTION; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; HALF LIFE TIME; LUNG; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOTRANSFORMATION; COLISTIN; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 84912133849     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03508-14     Document Type: Article

References (23)

1. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601. http://dx.doi.org/10.1016/S1473-3099(06)70580-1.
2. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gramnegative bacteria. Antimicrob. Agents Chemother. 53:3430-3436. http: //dx.doi.org/10.1128/AAC.01361-08.
3. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. 2010. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob. Agents Chemother. 54:3783-3789. http://dx.doi.org/10.1128/AAC.00903-09.
4. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, III, Forrest A, Bulitta JB, Tsuji BT. 2010. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 1279-1291. http://dx.doi.org/10.1592/phco.30.12.1279.
5. Yahav D, Farbman L, Leibovici L, Paul M. 2012. Colistin: new lessons on an old antibiotic. Clin. Microbiol. Infect. 18:18-29. http://dx.doi.org/10 .1111/j.1469-0691.2011.03734.x.
6. Couet W, Grégoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin. Pharmacol. Ther. 89:875-879. http://dx.doi.org/10.1038/clpt.2011.48.
7. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2013. Consistent global approach on reporting of colistin doses to pro-mote safe and effective use. Clin. Infect. Dis. 58:139-141. http://dx.doi .org/10.1093/cid/cit680.
8. Gobin P, Lemaître F, Marchand S, Couet W, Olivier JC. 2010. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chroma-tography-tandem mass spectrometry (LC-MS/MS). Antimicrob. Agents Chemother. 54:1941-1948. http://dx.doi.org/10.1128/AAC.01367-09.
9. Marchand S, Frat JP, Petitpas F, Lemaître F, Gobin P, Robert R, Mimoz O, Couet W. 2010. Removal of colistin during intermittent haemodialysis in two critically ill patients. J. Antimicrob. Chemother. 65:1836-1837. http://dx.doi.org/10.1093/jac/dkq185.
10. Lavielle M. 2008, posting date. Monolix (MOdèles NOn LInéaires à effets miXtes). Lixoft, Orsay, France.
11. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 47:1766-1770. http://dx.doi.org/10 .1128/AAC.47.5.1766-1770.2003.
12. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504. http://dx.doi .org/10.1023/A:1012299115260.
13. Boisson M, Jacobs M, Grégoire N, Gobin P, Marchand S, Couet W, Mimoz O. 2014. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob. Agents Chemother. 58:7331-7339. http://dx.doi.org/10.1128 /AAC.03510-14.
14. Le Gall JR, Lemeshow S, Saulnier F. 1993. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963. http://dx.doi.org/10.1001/jama.1993 .03510240069035.
15. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulphonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob. Agents Chemother. 56: 4241-4249. http://dx.doi.org/10.1128/AAC.06426-11.
16. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup. 2004. Acute renal failure- definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8:R204-R212. http://dx.doi.org/10.1186/cc2872.
17. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294. http://dx.doi .org/10.1128/AAC.01733-10.
18. Couet W, Grégoire N, Marchand S, Mimoz O. 2012. Colistin pharmacokinetics: the fog is lifting. Clin. Microbiol. Infect. 18:30-39. http://dx .doi.org/10.1111/j.1469-0691.2011.03667.x.
19. Wells M, Lipman J. 1997. Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function. S. Afr. J. Surg. 35:20-23.
20. He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T, Li J. 2013. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J. Antimicrob. Chemother. 68:2311-2317. http://dx.doi.org/10.1093/jac/dkt207.
21. Tsuji BT, Bulitta JB, Brown T, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Skerlos L, Hanna D. 2012. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J. Antimicrob. Chemother. 67:2182-2190. http://dx.doi.org/10.1093/jac/dks201.
22. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. 2012. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin. Infect. Dis. 54:1720-1726. http://dx .doi.org/10.1093/cid/cis286.
23. Roberts JA, Lipman J. 2012. Editorial commentary: closing the loop-a colistin clinical study to confirm dosing recommendations from PK/PD modeling. Clin. Infect. Dis. 54:1727-1729. http://dx.doi.org/10.1093/cid /cis311.